Table 1 Characteristics of trials
From: An investigation of the impact of futility analysis in publicly funded trials
| Â | Trial characteristics | Number (%) | Mean (SD) | Minimum - maximum | Successful (%) |
|---|---|---|---|---|---|
Funding body | HTA | 15 (45.4) | Â | Â | 4 (26.7) |
MRC | 18 (54.5) | Â | Â | 4 (22.2) | |
Endpoint | Binary | 20 (60.6) | Â | Â | 4 (20.0) |
Continuous | 13 (39.4) | Â | Â | 4 (30.8) | |
Disease | Cancer | 2 (6.1) | Â | Â | 0 (0.0) |
Area | Mental health (including neurosciences/psychiatry/psychology) | 5 (15.2) | Â | Â | 3 (60.0) |
| Â | Orthopaedics/rheumatology (including back pain) | 1 (3.1) | Â | Â | 0 (0.0) |
| Â | Obstetrics & gynaecology | 2 (6.1) | Â | Â | 1 (50.0) |
| Â | Primary care | 7 (21.2) | Â | Â | 2 (28.6) |
| Â | Cardiology | 3 (9.1) | Â | Â | 0 (0.0) |
| Â | Gastroenterology | 0 (0.0) | Â | Â | 0 (0.0) |
| Â | Incontinence/urology | 2 (6.1) | Â | Â | 0 (0.0) |
| Â | HIV/AIDS | 1 (3.0) | Â | Â | 0 (0.0) |
| Â | Other | 10 (30.3) | Â | Â | 2 (20.0) |
Planned sample size | Â | Â | 751.4 (1426.9) | 80 to 8,000 | Â |
Final sample size | Â | Â | 615.2 (1452.1) | 44 to 8,164 | Â |
Power | Â | Â | 84.2 (5.2) | 80 to 95 | Â |